Ovarian/Peritoneal/Fallopian Tube Cancer

Show Only Open Trials
2.

Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Immunomedics
  • Disease Status and/or Stage: Metastatic Epithelial Cancer
4.

A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL

  • Study Status: Open to Enrollment
  • Sponsor: Gynecologic Oncology Group; National Cancer Institute
  • Disease Status and/or Stage: Locally Advanced Cervical Cancer
5.

Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma

  • Study Status: Open to Enrollment
  • Sponsor: Montefiore Medical Center
  • Disease Status and/or Stage: Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
6.

A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer

  • Study Status: Closed to Enrollment
  • Sponsor: Mayo Clinic, National Cancer Institute
  • Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
7.

A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Solid Tumor

Top of page